Meta-analysis: Lipoprotein(a) Levels Independently Linked with Cardiovascular Disease Risk

Elevated baseline lipoprotein(a) levels (both on-statin and not on-statin) showed a strong linear relationship with risk for cardiovascular disease, according to the results of a new meta-analysis published in The Lancet.  

Researchers for the study looked at patient-level data from seven randomized, placebo-controlled statin outcomes trials and then calculated hazard ratios for cardiovascular events (fatal or nonfatal coronary heart disease, stroke, or revascularization procedures). The analysis included data from 29,069 patients with repeat lipoprotein(a) measurements.

According to the results, the initiation of statin therapy reduced low-density lipoprotein cholesterol (LDL-C) but was not associated with a significant change in lipoprotein(a) levels. The relationship between lipoprotein(a) and cardiovascular disease risk was linear, with lipoprotein(a) values of 30 mg/dL or more for baseline lipoprotein(a) or 50 mg/dL or greater for on-statin lipoprotein(a) linked with increased cardiovascular risk. The linear association was more pronounced for the on-statin lipoprotein(a) group compared to the on-placebo lipoprotein(a) group. 

“In this individual-patient data meta-analysis of statin-treated patients, elevated baseline and on-statin lipoprotein(a) showed an independent approximately linear relation with cardiovascular disease risk,” the researchers concluded. “This study provides a rationale for testing the lipoprotein(a) lowering hypothesis in cardiovascular disease outcomes trials.” 

Source: The Lancet